| Initiated MC/DC (n = 480) | Never used MC/DC (n = 14,309) | P value |
---|---|---|---|
Age (years) | 58.35 (11.60) | 59.76 (13.28) | 0.021 |
Male sex (%) | 20.83 | 22.23 | 0.469 |
Rheumatoid arthritis duration (years) | 14.77 (10.92) | 13.70 (11.05) | 0.036 |
Education (years) (0 to 17) | 13.70 (2.32) | 13.52 (2.33) | 0.106 |
Caucasian, non-Hispanic (%) | 93.68 | 89.72 | 0.005 |
Income (US$) | 46,698 (28,088) | 46,309 (29,352) | 0.775 |
Semi-annual costs (US$) | 6,007 (10,635) | 5,685 (7,835) | 0.406 |
Semi-annual drug costs (US$) | 4,073 (8,522) | 3,826 (6,528) | 0.098 |
Insurance (%) | Â | Â | 0.044 |
   Private | 29.17 | 27.26 |  |
   Health maintenance organization | 11.25 | 8.64 |  |
   Medicare | 41.67 | 47.10 |  |
   Preferred provider organization | 10.00 | 9.27 |  |
   Medicaid | 4.79 | 5.77 |  |
   No insurance | 3.13 | 1.95 |  |
Lifetime DMARDs | 2.90 (1.83) | 2.13 (1.54) | < 0.001 |
Lifetime DMARDs and biologics | 3.30 (2.10) | 2.52 (1.81) | < 0.001 |
Prednisone (%) | 40.08 | 35.34 | 0.033 |
Methotrexate (%) | 49.48 | 50.48 | 0.667 |
Comorbidity index (0 to 9) | 1.68 (1.46) | 1.59 (1.48) | 0.193 |
Health Assessment Questionnaire (0 to 3) | 1.06 (0.71) | 1.04 (0.73) | 0.474 |
Physical component summary score (0 to 100) | 35.03 (11.17) | 36.39 (11.09) | 0.008 |
Mental component summary score (0 to 100) | 50.02 (11.30) | 49.11 (11.49) | 0.086 |
Patient global (0 to 10) | 3.47 (2.50) | 3.50 (2.53) | 0.784 |
Pain (0 to 10) | 3.92 (2.82) | 3.83 (2.79) | 0.506 |
Patient Activity Scale (0 to 10) | 3.64 (2.27) | 3.60 (2.24) | 0.666 |